Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, agosto 19
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
BridgeBio Pharma Inc
BBIO
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$82.98
3.09
3.87%
al cierre: Aug 18, 5:00 PM EST
$82.98
N/A
After hour: 4:00 PM EST
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
BridgeBio Pharma Financials
BridgeBio Pharma (BBIO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
BridgeBio Pharma Q2 EPS $(0.78) Misses $(0.59) Estimate, Sales $243.676M Beat $218.743M Estimate
BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.59) by 32.2 percent. This is a 17.89 percent increase over losses of $(0.95) per share
Benzinga Newsdesk
PRO
BridgeBio Pharma Q1 EPS $(0.84) Misses $(0.67) Estimate, Sales $194.515M Beat $177.937M Estimate
BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.67) by 25.37 percent. This is a 4.55 percent increase over losses of $(0.88) per share from
Benzinga Newsdesk
BridgeBio Pharma Earnings Review: Q4 Summary
Benzinga Insights
PRO
BridgeBio Pharma Q4 EPS $(1.00) Misses $(0.66) Estimate, Sales $154.178M Beat $146.844M Estimate
BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.66) by 52.67 percent. This is a 28.57 percent increase over losses of $(1.40) per share
Benzinga Newsdesk
Earnings Scheduled For February 24, 2026
Benzinga Insights
Insights Ahead: BridgeBio Pharma's Quarterly Earnings
Benzinga Insights
Privacy Manager